COVID trials in PH: What to expect

No images? Click here       News Duterte asks Apec: Ensure universal access to vaccine President Duterte stressed the need for countries to ensure universal access to a COVID-19 vaccine and to keep trade free, open, and fair in order to achieve comprehensive and inclusive economic recovery in the face of the pandemic. - STORY BY LEILA B. SALAVERRIA  Read more:  https://philippinedailyinquirerplus.pressreader.com/@nickname19452911/csb_Np5oYVEKQUp_Lgn2vXAgs3DljXvIGHyBbO2h4VHG1a-xHNtR5l86IQ4af503T9pO   Regions Tarlac's Belenismo: Holiday glow trumps pandemic gloom   TARLAC CITY—At a time when Filipinos are desperately looking for a respite from the seemingly never ending tragedies this year, the annual display of colorful nativity dioramas in Tarlac province is offering hope and breathing space. —STORY BY MARIA ADELAIDA CALAYAG  Read more: https://philippinedailyinquirerplus.pressreader.com/@nickname19452911/csb_Np5oYVEKQUp_Lgn2vXAgs0geFiYotV2KJAPL2iBESwZVp-n4uTMFEcLtm9m1qntD   Lifestyle Tourism's immediate future: Road trips, staycations There’s something surreal about our country winning all these travel awards right in the middle of a pandemic, when most of the world is unable to travel, and our borders are still closed to international tourists.  —STORY BY BERNADETTE ROMULO-PUYAT Read more:  https://philippinedailyinquirerplus.pressreader.com/@nickname19452911/csb_Np5oYVEKQUp_Lgn2vXAgs_997_bSY8ZnmEJiyKXj0QtNrBWsAFcqJjgFBb3XBANA     Sunday Biz Choose local, buy local    The COVID-19 hit our communities slowly, and then all at once. In the beginning, the daily wage earners and jeepney drivers were hard-hit. —STORY BY ADELLE ASPACIO  Read more:   https://philippinedailyinquirerplus.pressreader.com/@nickname19452911/csb_Np5oYVEKQUp_Lgn2vXAgs2QB8f1hrQP-cIS6-bxPOdpqJ1EgOeEyNFMNaJIAwTLH     Newsletter / Join us Has this been forwarded by a friend? Subscribe now to the Philippine Daily Inquirer Newsletters and get your latest news and important updates straight to your device. Subscribe   READ MORE     Banner story COVID vaccine trials in PH: What to expect   In about a month’s time, Filipinos may start taking part in the biggest global effort to find a vaccine to end “one of the most devastating epidemics” humanity has had to face. The clinical trials for a COVID-19 vaccine in the Philippines are going to be different from those it had hosted in the past, given the high stakes after the new coronavirus had already killed more than 1.3 million people in 191 countries nearly a year since the outbreak in China. More than a hundred vaccines against SARS-CoV-2, the virus that causes the severe respiratory disease, are being developed worldwide and undergoing various stages of clinical trials. Such trials ensure that a vaccine is both safe and effective for people. A candidate vaccine first undergoes a preclinical trial in which it is tested on mice and monkeys to see if it produces the desired immune response. After that stage, the vaccine goes on to three phases of human trials. Phase 1 involves a small number of people, typically between 10 to 100 to test the vaccine’s safety. A much larger group of at least 100 to 1,000 people are enrolled in Phase 2 to determine its effectiveness and the right dosage. For Phase 3, at least 1,000 are enrolled to confirm the vaccine’s safety and efficacy. Leading candidates Barely 11 months since the virus emerged from a wet market in Wuhan, China, two candidate vaccines have been found to be 95-percent effective. These vaccines were developed by Pfizer/BioNTech and Moderna and the US National Institutes of Health, which did not hold clinical trials in the Philippines. The country, however, will take part in an international Solidarity Trial on Vaccines led by the World Health Organization (WHO). Separately, at least five other pharmaceutical groups have either expressed their intention or are trying to secure clearance to hold their Phase 3 trials in the country. These independent trials are for vaccines developed by China’s Sinovac and Clover Biopharmaceuticals, Russia’s Gamaleya Research Institute, Johnson&Johnson of the United States and the United Kingdom’s AstraZeneca.Sinovac is ahead of the others as it now awaits approval to begin its Phase 3 trial from the ethics board of the Department of Health. It would need at least 1,000 volunteers or participants. Participant pool Science Secretary Fortunato dela Peña said the WHO Solidarity Trial, which could involve four candidate vaccines, may begin in December, with its pilot in the Americas expected to start this month. The WHO had asked the Philippine government to increase its participant pool from 2,000 to 4,000. To determine a vaccine’s effectiveness, a trial participant is given the vaccine or a placebo. According to Dr. Lulu Bravo, executive director of the Philippine Foundation for Vaccination, neither the participant nor the health worker knows what the volunteer was injected with. Only the members of the data safety and monitoring board overseeing the trials know, said Bravo, a pediatric infectious disease expert who has participated in various clinical trials over the last three decades. Once inoculated, trial participants can go about their usual activities. They will be constantly checked by researchers and must report to trial investigators if anything feels amiss. Don’t be complacent The participants must not be complacent and should continue to observe the minimum health measures to avoid contracting the virus like everyone else, Bravo said. If an “adverse health event” is recorded in any of the trial participants, the data and safety and monitoring board has the power to halt the study or the trial sponsor can implement a pause. Volunteers, who are asked to sign an informed consent form, are not paid and may even receive a small “allowance.” The company concerned must cover the medical expenses incurred by the volunteer in case of an adverse event related to the candidate vaccine. According to Sanofi Pasteur Philippines general manager Dr. Jean-Antoine Zinsou, a temporary pause on a candidate’s vaccine trial should not cause alarm as this only shows that the trial monitoring is working.“This is a very good signal when you have companies interrupting a study, it means people are not rushing, they are doing things properly,” he said.“We need to admit the fact that whatever the quality of a Phase 3 study, it will never ever cover all the specificity in the world and therefore there will be some adjustment of the indication along the way,” he said. “What’s important is whenever you have an adverse event, it is properly managed.” Read full story:   https://philippinedailyinquirerplus.pressreader.com/@nickname19452911/csb_Np5oYVEKQUp_Lgn2vXAgs80S6-VZ1Ot2i-y9uaSlgN6M-HI2saOlDXjKB4KpqPz7   Get here   Copyright © 2020 PHILIPPINE DAILY INQUIRER, All rights reserved. Our mailing address is: P.O. Box 2353, Makati Central Post Office, 1263 Makati City, Philippines.   Share    Tweet    Share    Forward  Preferences  |  Unsubscribe